Sanofi Makes Big Strides In Eradicating Sleeping Sickness
Acoziborole Cured 95% of People With Late-Stage Disease
Executive Summary
The positive Phase II/III results for acoziborole have led researchers to claim that the goal of eliminating sleeping sickness by 2030 is now very much a reality.
You may also be interested in...
Sanofi Puts Faith In Rare Review Procedure For ‘Breakthrough’ Sleeping Sickness Drug
Sanofi believes its fully oral sleeping sickness treatment, fexinidazole, will support efforts to eliminate the disease by 2020. The European Medicines Agency is set to start reviewing the product soon with a view to it being used in Africa.
The Game Looks Up For Galecto
The Boston-based biotech is weighing up its options as the fall-out from its failed IPF candidate casts a shadow over Galecto’s future.
What Verona Needs To Make COPD Drug Ensifentrine A Success
Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.